# A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants

> **NCT06719128** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 46 (actual)

## Conditions studied

- Hepatic Insufficiency
- Healthy

## Interventions

- **DRUG:** Olomorasib

## Key facts

- **NCT ID:** NCT06719128
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-12-06
- **Primary completion:** 2025-08-25
- **Final completion:** 2025-08-25
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2025-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06719128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06719128, "A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT06719128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*